Home
    • Plans Blog Contact
    Kazia Therapeutics Ltd ADR logo

    Kazia Therapeutics Ltd ADR

    KZIA
    Last price US$12.22
    Market cap US$10.7b
    12M price change 22.69%
    Loading the 12-month Mave Thesis and 1-month news signal

    Industry and sector peers, plus broader research alternatives

    View comparison
    Syneos HealthSYNH Industry peer Pluri IncPLUR Industry peer Prenetics Global LtdPRE Industry peer Zoetis IncZTS Sector peer
    Overview Earnings Report Price History News Competitors Earnings per Share Return on Equity Net Margin Share Buyback Leverage Financial Statements Financial Ratio
    Dashboard Funda..tals Prediction Screener Map

    Kazia Therapeutics Ltd ADR Overview

    Industry: Biotechnology & Medical Research

    Sector: Healthcare

    Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. It is also developing EVT801, an investigational new drug for various forms of cancer. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. The company was incorporated in 1994 and is based in Sydney, Australia. Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. It is also developing Read More

    Mavefund brings filings, fundamentals, valuation, price history and news for Kazia Therapeutics Ltd ADR into one research view. The sections below show what strengthens or weakens the research case.

    Score

    Reported Results

    What the company reported, with filing details kept small.

    Filed Jun 02, 2026

    Quarterly result summary

    Exhibit 99.1 Kazia Therapeutics Appoints James Levine as Chief Financial Officer SYDNEY, Australia, June 2, 2026 – Kazia Therapeutics Limited (NASDAQ: KZIA) (“Kazia,” “Kazia Therapeutics” or the “Company”), a clinical-stage oncology company advancing therapie...

    What changed

    • Review the SEC source filing for the full reported results and management commentary.

    Guidance / outlook

    we expect to be a period of meaningful clinical and strategic milestones for the Company.

    Earnings release Open filing

    Source: SEC EDGAR company-filed earnings materials. Dates are shown only for verification; review the source filing before relying on extracted report details.

    Other recent earnings materials
    SEC filing REPORT OF FOREIGN PRIVATE ISSUER May 26, 2026 Earnings release PRESS RELEASE DATED MAY 26, 2026 May 26, 2026 SEC filing FACT SHEET DATED APRIL 27, 2026 Apr 27, 2026 Earnings release PRESS RELEASE DATED APRIL 15, 2026 Apr 15, 2026 SEC filing REPORT OF FOREIGN PRIVATE ISSUER Apr 15, 2026 Earnings release PRESS RELEASE DATED APRIL 13, 2026 Apr 13, 2026 SEC filing REPORT OF FOREIGN PRIVATE ISSUER Apr 13, 2026 SEC filing FACT SHEET DATED MARCH 27, 2026 Mar 31, 2026 SEC filing FORM 10Q 2006 09 Nov 07, 2006

    Prediction-grade evidence

    Recent News

    Company-relevant articles from sources that pass the Mave Signal relevance and reliability checks.

    No qualified company news in the last 14 days

    No recent article passed both the company-relevance and source-reliability checks. Research continues to use the other available filings, fundamentals, market data, and valuation inputs.

    Earnings Per Share

    Score 4.00/5
    Kazia Therapeutics Ltd ADR boasts a high score, as its Earnings Per Share (EPS) has demonstrated consistent growth over the past six years. Notable counterparts in the sector with high scores includes Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
    In Biotechnology & Medical Research industry , Syneos Health , Pluri Inc , Prenetics Global Ltd are companies with high ratings.

    Return on Equity

    Score 1.96/5
    Kazia Therapeutics Ltd ADR exhibits a lower score in the Return on Equity (ROE) section, falling below the sector median value and indicating a comparatively weaker performance in this metric. The top companies in the same sector include Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
    Kazia Therap... KZIA US$10.7b
    Zoetis Inc ZTS US$31.9b
    IQVIA Holdin... IQV US$34.8b
    Agilent Tech... A US$37.9b

    Net Margin

    Score 2.21/5
    Kazia Therapeutics Ltd ADR olds a low score as its net margin consistently trails below the sector median value and doesn't exhibit continuous growth over the last six years; notable companies in the sector with commendable scores include Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
    Kazia Therap... KZIA US$10.7b
    Zoetis Inc ZTS US$31.9b
    IQVIA Holdin... IQV US$34.8b
    Agilent Tech... A US$37.9b

    Share Buyback

    In Biotechnology & Medical Research industry , Syneos Health , Pluri Inc , Prenetics Global Ltd are companies with high ratings.

    Leverage

    Score 2.44/5
    Kazia Therapeutics Ltd ADR registers a lower score in the category as a result of its elevated leverage ratio over the past six years compared to the sector median value. Conversely, other companies in the same sector, including Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc have achieved high scores.
    Kazia Therap... KZIA US$10.7b
    Zoetis Inc ZTS US$31.9b
    IQVIA Holdin... IQV US$34.8b
    Agilent Tech... A US$37.9b

    Financial Statements

    Company-reported SEC EDGAR facts organized into the three core statements.

    Verified SEC statements load when this section enters view.

    Source: SEC EDGAR companyfacts. Values are standardized company filings for research support, not personalized financial advice.

    Financial Ratio

    Yearly Quarterly

    Financial
    Profitability
    Growth
    Cash Flow
    Financial Health
    Efficiency Ratios

    Kazia Therapeutics Ltd ADR logo

    Kazia Therapeutics Ltd ADR

    US$12.22

    US$10.7b

    -8.40%

    22.69%